Illumina-University of Melbourne Partnership
Partnering to provide the infrastructure, expertise, systems and analysis to translate and implement genomics into routine clinical care.
Genomics-driven personalised care presents an incredible opportunity to transform patient outcomes and create substantial efficiencies for the healthcare system.
Illumina and the University of Melbourne are partnering affordable, scaleable next-generation sequencing with the research expertise, infrastructure, systems and analysis needed to implement genomics into routine clinical care.
Based in the Melbourne Biomedical Precinct, our collaborative, cross-disciplinary approach translates evidence-based advancements into the clinic, supporting local training and jobs.
The Illumina-University of Melbourne partnership will lift local genomics research and clinical trials to a global scale and quality, driving collaboration within the Precinct through the development of three core enabling platforms in clinical genomics, bioinformatics, and health economics.
Announcing The Illumina-University of Melbourne Genomics Hub
Illumina and University of Melbourne, together with Invest Victoria, are excited to launch The Illumina-University of Melbourne Genomics Hub. Find out more about how the Hub will become a key driver in building workforces and businesses of the future, delivering first-hand, practical experience and fostering a pipeline of commercially focused genomics innovation projects.
The core enabling platforms
The establishment of three core enabling platforms is vital to fostering a pipeline of commercially focused genomic innovation projects. Together with Illumina’s commercial expertise and global connections, the core platforms will enable the Melbourne Biomedical Precinct to capitalise on its competitive advantage in genomics research thanks to our world-leading researchers. The platforms will be underpinned by cloud-based informatics infrastructure enabling the delivery of genomics at scale for flagship and future innovation projects.
-
Clinical Genomics Platform
Expanding the patient sequencing capacity of the Melbourne Biomedical Precinct.
-
Bioinformatics Platform
Building the infrastructure and personnel to rapidly analyse large datasets of patient genomic information.
-
Health Economics Platform
Enabling rapid translation of genomics into health services through treatment modelling to highlight improved clinical results and economic benefits.
Flagship research programs
Researchers from the University of Melbourne and Peter Doherty Institute are leading the first flagship genomic innovation projects, leading the way for the future pipeline of commercially focused genomics innovation projects to utilise the partnership's infrastructure and expertise.
-
Cancer of Low Survival and Unmet Need Initiative
Sequencing genomes of the most challenging cancer cases in real-time for personalised clinical treatment and care.
-
ID Predict: A genomics-focused platform for treatment of COVID-19 and other infectious diseases
Genomics platform to understand the varied types of disease progression of patients with COVID-19, which will help to identify what treatment is best suited to individual patients.
-
Cancer Liquid Biopsy: Non-invasive blood-based monitoring for cancer
Using genomic tools for detection and monitoring of circulating tumour DNA (ctDNA) in patient blood samples to enable cancer detection, surveillance and recurrence screening
Latest news
The three core enabling platforms of the Illumina-University of Melbourne partnership are vital to fostering a pipeline of commercially focused genomic innovation projects.
Together with Illumina’s commercial expertise and global connections, the core platforms will enable the Melbourne Biomedical Precinct to capitalise on its competitive advantage in genomics research thanks to our world-leading researchers. The platforms will be underpinned by cloud-based informatics infrastructure enabling the delivery of genomics at scale for flagship and future innovation projects.
-
Bioinformatics Platform
Building the infrastructure and personnel to rapidly analyse large datasets of patient genomic information.
-
Health Economics Platform
Enabling rapid translation of genomics into health services through treatment modelling to highlight improved clinical results and economic benefits.
-
Clinical Genomics Platform
Expanding the patient sequencing capacity of the Melbourne Biomedical Precinct.
Projects enabling the rapid translation of research to quickly and effectively act on health threats such as cancer and infectious disease.
Researchers from the University of Melbourne and Peter Doherty Institute are leading the first flagship genomic innovation projects, leading the way for the future pipeline of commercially focused genomics innovation projects to utilise the partnership's infrastructure and expertise. The Cancer of Low Survival and Unmet Need health systems innovation project aims to improve diagnosis and provide more targeted and effective treatments for cancers of unmet need.
-
Cancer of Low Survival and Unmet Need Initiative
Sequencing genomes of the most challenging cancer cases in real-time for personalised clinical treatment and care.
-
ID Predict: A genomics-focused platform for treatment of COVID-19 and other infectious diseases
Genomics platform to understand the varied types of disease progression of patients with COVID-19, which will help to identify what treatment is best suited to individual patients.
-
Cancer Liquid Biopsy: Non-invasive blood-based monitoring for cancer
Using genomic tools for detection and monitoring of circulating tumour DNA (ctDNA) in patient blood samples to enable cancer detection, surveillance and recurrence screening
Genomics-driven personalised care presents an incredible opportunity to transform patient outcomes and create substantial efficiencies for the healthcare system.
Illumina and the University of Melbourne are partnering affordable, scaleable next-generation sequencing with the research expertise, infrastructure, systems and analysis needed to implement genomics into routine clinical care.
Based in the Melbourne Biomedical Precinct, our collaborative, cross-disciplinary approach translates evidence-based advancements into the clinic, supporting local training and jobs.
The Illumina-University of Melbourne partnership will lift local genomics research and clinical trials to a global scale and quality, driving collaboration within the Precinct through the development of three core enabling platforms in clinical genomics, bioinformatics, and health economics.
-
The Illumina-University of Melbourne Genomics Hub
The Illumina UoM Genomics Hub will accelerate the translation and commercialisation of biomedical research into a cluster of high-growth, high-tech startups.
-
The need
Increasing genomics innovation and its translation and adoption into the healthcare system to improve patient outcomes.
-
Recruitment
Opportunities to join our core enabling research platforms and programs.
-
People
The researchers behind the core enabling platforms.
-
What is genomics?
Genomics is the study of genes and what they do.
Subscribe for updates and get in touch to see how you can be involved.
Media inquiries
Zoe Stephenson
Communications and Public Relations Manager
University of Melbourne Centre for Cancer Research
+61 466 566 004
zoe.stephenson@unimelb.edu.au